Combined Thrombin and Platelet Inhibition Treatment for HIT Patients

Summary

Despite the use of potent anticoagulants such as r-hirudin and argatroban, the morbidity and mortality in heparin-induced thrombocytopenia (HIT) patients remains unacceptable. Data from our in vitro investigations show that thrombin inhibitors do not block platelet activation induced by heparin antibodies and heparin but that GPIIb/IIIa receptor inhibitors do block this process. We have treated four HIT positive patients with a combined therapy of thrombin inhibitor and GPIIb/IIIa receptor inhibitor when treatment with thrombin inhibitor alone failed to alleviate acute thrombosis. Combination therapies included r-hirudin (Refludan^®) with tirofiban (Aggrastat^®) and argatroban (Novastan^®) with abciximab (ReoPro^®). A reduced dose of the thrombin inhibitor was used with the standard dose of the anti-platelet drug. In all cases, there was no overt bleeding which required intervention, and all patients exhibited clinical improvement or full recovery. These case studies suggest that treatment of active thrombosis in HIT patients with adjunct GPIIb/IIIa receptor inhibitor therapy may be more effective than thrombin inhibitor treatment alone.

Keywords

Platelets - heparin - thrombocytopenia - thrombin inhibitor - GPIIb/IIIa receptor inhibitor

• References

• 1 Wallis D.E, Lewis B.E, Walenga J.M. Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. A clinician’s perspective. Semin Thromb Hemost 1999; 25 (Suppl. 01) 3-8.
• 2 Warkentin T.E, Kelton J.G. A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
• 3 Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten H.G, Pötzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999; 99: 73-80.
• 4 Lewis B.E. Preliminary results of a prospective randomized controlled trial of argatroban vs. conventional therapy for heparin-induced thrombocytopenia. Presented at the Argatroban - A Novel Antithrombotic Drug for the Treatment of Heparin-induced Thrombocytopenia Symposium, Florence, Italy, June 12,1997.
• 5 Fareed J, Yang L.H, Hoppensteadt D, Koza M, Walenga J.M, Welzel D. Glycoprotein IIb/IIIa inhibitors can prevent heparin mediated platelet activation in heparin-induced thrombocytopenia. Circulation 1996; 94 Suppl. I 1228.
• 6 Jeske W.P, Walenga J.M, Szatkowski E, Ero M, Herbert J.M, Haas S, Bakhos M. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997; 88: 271-81.
• 7 Jeske W, Szatkowski E, Wood J.J, Messmore H.L, Herbert J.M, Walenga J.M. Inhibition of platelet activation in HIT: Thrombin inhibitors vs. anti-platelet agents. Blood 1998; 92 (Suppl. 01) 180a.
• 8 Walenga J.M, Jeske W, Wallis D.E, Lewis B.E, Leya F, Bakhos M, Fareed J. Clinical Experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patents with HIT. Semin Thromb He-most 1999; 25 (Suppl. 01) 77-81.
• 9 Amiral J, Martaing-Koka A, Ponca M, Meyer D. The biological basis of immune heparin-induced thrombocytopenia. Review. Platelets 1998; 9: 77-91.
• 10 Jeske W.P, Mousa S.A, Yang L.H, Fu K.D, Sheikh A, Ahmad S, Walenga J.M, Fareed J. Short-acting glycoprotein IIb/IIIa inhibitors may be safer for the management of patients with active heparin-induced thrombocytopenic syndrome. Blood 1998; 92 (Suppl. 01) 181a.
• 11 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
• 12 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein I Ib/I I la receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
• 13 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
• 14 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
• 15 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
• 16 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.